



Private Equity Pharmacy Benefit Solutions



**Improve Your Portfolio Company Pharmacy Expense with
Guaranteed Savings, Cost Predictability, and Transparent Results**

**Healthcare spend is the #2 line item on a
P&L— pharmacy is the #1 driver of that cost**

- Pharmacy is the fastest rising component of healthcare spend, with an **11.4% increase in 2023**, and represents the largest opportunity for savings
- Specialty medication spend is growing at a double-digit rate
- **13%** of employees drive **90%** of portfolio company pharmacy spend

Pharmacy is the #1 Health Benefit
used by portfolio company employees

62%

of our clients had a member who cost
the plan more than \$100,000 in 2024
— a 19% increase in 1 year!



Since 1995, RxBenefits has addressed the high pharmacy cost challenges of many self-funded employers by generating unprecedented savings and cost predictability. Today, we manage over 3M members and \$3B in annual pharmacy spend, including partnering with over 350 private equity sponsored companies representing 100+ private equity firms in the US.



What you can expect:

- Portfolio company EBITDA improvements due to superior first-year contract pricing and annual pricing enhancements
- Independent PharmD-led utilization management, with advanced oversight on expensive specialty medications, to further increase EBITDA with savings and quantified risk stratification
- Award-winning service that delivers high client and member satisfaction with limited disruption
- Predictable plan economics supported by ongoing data-driven insights


Manage **3M** members and **\$3B** in annual pharmacy spend

Partner with **350+** private equity sponsored companies representing **100+** private equity firms in the US

Data-driven insights uncover pharmacy risks and opportunities

Strategic Savings

By combining aggressive PBM negotiation with independent clinical utilization management we drive sustainable, year-over-year savings and proactively manage trend.



28%* First-year contract savings + **7-10%** clinical savings*

Results based on 2024 financial analysis

3 of 4 of our top 40 clients experienced flat or negative trend.

GLP-1 Savings

- Addressing off-label use of costly GLP-1s like Ozempic
- Confirming medical necessity and FDA-approved dosing
- \$52M 2024 BoB Savings (pre-rebate)

High-Cost Anti-inflammatory and Dermatologic Savings

- Proactive and retroactive Pharm-D led provider interventions
- Offers lower-cost, therapeutically appropriate alternatives for expensive specialty medications
- \$14.6M savings in 2024 (pre-rebate), ~\$45K in annualized gross savings per intervention

To learn more about RxBenefits' private equity solutions contact:

Peter Lombardi

Executive Advisor / Private Equity Business Development
at 415.516.0849 or plombardi@rxbenefits.com



RxBenefits.com | 800.377.1614

Copyright © 02.20.2025 RxBenefits, Inc. All Rights Reserved.